Schizophrenia is frequently a chronic and disabling disorder, characterized by
heterogeneous positive and negative symptom constellations. The objective of this review …

Abstract Purpose of Review We review recent developments on risk factors in
schizophrenia. Recent Findings The way we think about schizophrenia today is profoundly …

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

Schizophrenia is a severe neuropsychiatric disorder with a longstanding history of
neurobiological investigation. Although the underlying causal mechanisms remain …

Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-
HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific …

The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of
schizophrenia. Both were initially based on indirect evidence from pharmacological studies …

Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Abstract N-methyl-d-aspartate (NMDA) receptor (NMDAR) hypofunction plays a key role in
pathophysiology of schizophrenia. Since NMDAR hypofunction has also been reported in …

How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently
disabling mental disorder that affects about one per cent of the world's population. After a …